Opus Genetics, Inc. (IRD) Investor Relations Documents

Opus Genetics, Inc. (IRD) investor relations documents from the company's IR site: 3 presentations, 22 press releases; latest deck 2026-07-08. Read in-app with summaries. First-party data.

July 2026 Investor Presentation: Opus Genetics is a gene therapy company developing seven AAV-based treatments for inherited retinal diseases, currently fully funded for five clinical programs.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-19	Press release	Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-06	Press release	Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
2026-08-03	Press release	Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Re
2026-07-09	Press release	Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
2026-07-08	Presentation	July 2026 Investor Presentation
2026-07-06	Press release	Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited
2026-06-26	Press release	Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
2026-06-16	Press release	Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal
2026-06-02	Press release	Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease E
2026-05-28	Press release	Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-28	Press release	Download as PDF
2026-05-27	Press release	Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-17	Presentation	View Investor Presentation
2026-05-13	Press release	Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
2026-05-13	Presentation	OPGx-BEST1 Cohort 1 Baseline Demographics and Key Endpoints for IRDs Presentation (PDF)
2026-05-12	Press release	Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
2026-05-12	Press release	Download as PDF
2026-05-07	Press release	Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inheri
2026-04-27	Press release	Opus Genetics to Participate in Leading Medical Conferences in May 2026
2026-03-24	Press release	Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
2026-03-10	Press release	Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
2026-03-03	Press release	Opus Genetics to Present at Upcoming Investor Conferences in March 2026
2026-02-02	Press release	Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
2025-03-31	Press release	Opus Genetics Announces Financial Results for Full Year 2024
2024-11-12	Press release	Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update

IRD overview · IRD earnings · IRD financials · IRD KPIs · IRD ownership · IRD peers · IRD filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.